Gilead Sciences is a biopharmaceutical company focused on advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Co. emphasizes the discovery, development, and commercialization of medicines for unmet medical needs. Its marketed products include AmBisome, Atripla, Biktarvy, Descovy (including for PrEP), Epclusa, Genvoya, Harvoni, Sovaldi, Truvada (including for PrEP), Veklury, Vemlidy, Viread, Yescarta, and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Domvanalimab, Zimberelimab, and Seladelpar for treating primary biliary cholangitis (PBC). Co. operates in over 35 countries.
When researching a stock like Gilead Sciences, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from GILD Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for GILD stock — the real life supply and demand for the stock over time — and examines that data in different ways. |
53.16
Free GILD Email Alerts:
Video: Technical Analysis